- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 134 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 133 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 140 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
From €2243EUR$2,500USD£1,931GBP
- Report
- November 2023
- 262 Pages
Global
From €6730EUR$7,500USD£5,792GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
Adefovir is a nucleotide analog antiviral drug used to treat chronic hepatitis B virus (HBV) infection. It is also used to treat kidney disorders caused by the virus. Adefovir works by blocking the activity of the virus in the body, preventing it from replicating and causing further damage. Adefovir is usually taken orally in the form of a tablet or capsule. It is also available as an injection. Adefovir is generally well tolerated, but can cause side effects such as nausea, vomiting, and diarrhea.
Adefovir is a widely used drug for the treatment of chronic HBV infection and kidney disorders. It is an important part of the treatment regimen for these conditions, as it can help reduce the risk of further damage to the liver and kidneys. Adefovir is also used in combination with other antiviral drugs to increase the effectiveness of treatment.
Some companies that produce Adefovir include Gilead Sciences, Merck, and Bristol-Myers Squibb. These companies produce Adefovir in various forms, including tablets, capsules, and injections. Show Less Read more